KFF Health Tracking Poll: Knowledge and Views of Medication Abortion
This KFF Health Tracking Poll finds that many, including women of reproductive age, remain unfamiliar…
KFF Health Tracking Poll: Knowledge and Views of Medication Abortion
This KFF Health Tracking Poll finds that many, including women of reproductive age, remain unfamiliar with key facts about mifepristone. Fewer than half of all adults say they believe abortion pills are safe now, compared to over half of all adults two years ago. This poll explores awareness and perception of the recent FDA review…
Mientras científicos estudian la propagación del sarampión en el país, Kennedy pone en riesgo avances que costaron décadas
Estados Unidos está a punto de perder su estatus de país libre de sarampión el próximo año. Si eso sucede, entraría en una nueva etapa en la que los brotes volverían a ser comunes. Más niñas y niños serían hospitalizados por esta enfermedad prevenible. Algunos perderían la audición. Algunos morirían. El sarampión también es costoso….
While Scientists Race To Study Spread of Measles in US, Kennedy Unravels Hard-Won Gains
The United States is poised to lose its measles-free status next year. If that happens, the country will enter an era in which outbreaks are common again. More children would be hospitalized because of this preventable disease. Some would lose their hearing. Some would die. Measles is also expensive. A new study — not yet…
Health Savings Accounts, Backed by GOP, Cover Fancy Saunas but Not Insurance Premiums
With the tax-free money in a health savings account, a person can pay for eyeglasses or medical exams, as well as a $1,700 baby bassinet or a $300 online parenting workshop. Those same dollars can’t be used, though, to pay for most baby formulas, toothbrushes — or insurance premiums. President Donald Trump and some Republicans…
Slaying The Dragon
By MIKE MAGEE The date was June 9, 1954. This was over a year after Wisconsin Republican Senator Joseph R. McCarthy had assumed the chairmanship of the Senate Permanent Subcommittee on Investigations. The history shows that he had “rocketed to public attention in 1950 with his allegations that hundreds of Communists had infiltrated the State Department…
Why Epic’s Judy Faulkner Rejects the MBA Mindset
At Forbes Healthcare Summit, Epic CEO Judy Faulkner explained why the company’s long-protected independence and unconventional management approach have been central to its dominance as an EHR vendor. Now, she says the company’s future will depends on how it uses its massive data stores to support AI-powered clinical decisions. The post Why Epic’s Judy Faulkner…
Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App
Empathy Health’s $7.6 million round was led by HealthX Ventures and included participation from Nina Capital, Ikigai Healthcare Funds, American Heart Association Ventures, Suncoast Ventures, Cortado Ventures and Wilson Sonsini Investment Company. The post Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App appeared first on MedCity News.
What the Health? From KFF Health News: The GOP Still Can’t Agree on a Health Plan
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Debunked Episode 22: With ACA Subsidies Set to Expire and the Open Enrollment Window Closing, Members of Congress Brainstorm Alternatives
What are the alternatives to extending ACA subsidies for the 22 million people who purchase health plans on the ACA Marketplace? That’s the focus of the latest episode of the Debunked podcast, hosted by MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. The post Debunked Episode 22:…
Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance
Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans. The post Crescent Bio Expands Its Cancer Drug Combo Ambitions…
